Every letter we have printed

Your needle-length section says four millimetres is adequate for all adults, which contradicts what I was told by a nurse who insisted on half an inch because of my weight. Which is right?

You recommend writing the concentration on the vial. I would add: write it on the box as well. My vial label came off in the fridge and I lost the only record of what diluent volume I had used.

Your incidence tables are from the licensed products. I use compounded material at a concentration that does not match any pen. Are the figures transferable at all?

You note that symptom burden does not predict weight outcome. This is the single most useful sentence I have read about this treatment. I spent four months believing that feeling well meant it was not working and considered increasing my dose on that basis alone.

Nothing in your file addresses the social dimension, which for me was worse than the nausea. Six months of declining invitations to meals, and explaining to family why I was not eating. The tables do not have a row for that.

A small point of precision. You use "gastroparesis" in the tag list and then spend a paragraph saying it is not a synonym for drug-induced emptying delay. That is a slightly awkward position to hold.

I stopped at week six because I could not keep anything down for three days, and my prescriber told me I had not given it a fair chance. Reading your definition of dose-limiting, I think what happened was that nobody offered me the option of going back to the lower dose. It was escalate or stop.

I take this for kidney disease, not for weight. Every piece of writing I encounter about stopping is about the weight coming back. It has taken me a year to find anybody willing to say plainly that the renal benefit accrued over years of treatment and nobody has tested what happens if I stop.

The claim that stopping does not leave you worse off than baseline is a group-level claim about trial arms. Individuals can and do overshoot. Your phrasing invites readers to conclude otherwise.

Three months after stopping, my HbA1c had barely moved and I concluded I had got away with it. Six months after stopping, it was back where it started. Your point about the lag is the single most useful sentence I have read on this subject.

Your fortnightly arithmetic table is correct but I think it understates the practical point. A fourfold peak-to-trough swing is not merely lower average exposure; it is a different drug experience, with the last few days of each cycle spent at a concentration the person has effectively titrated off.

On amber glass: it is not merely cheap, it is standard in the wider chemical supply trade for anything with a chromophore. The fact that this market ships peptides in clear glass is a sign of who is doing the filling more than of any decision about photostability.

You give the reference change value for ALT as about sixty per cent, which strikes me as so large as to make routine monitoring of it pointless. Is that your position?

As a biomedical scientist I would add one point to your reference-interval section: many laboratories do not derive their own intervals at all. They adopt the manufacturer interval for the platform, which was established in a population that may have nothing to do with the one being tested. The interval on the report can be a document about a different country.

VendorInvestigate does not measure anything and you have grouped it with three laboratories under the heading independent testing. That is exactly the conflation your article says the market makes.

On the archive point: a public record of submissions by vendor would be gamed within a month. Vendors would submit under the names of resellers, or through intermediaries, and the archive would show a distribution as selected as the current one but with a veneer of completeness.

Three vendors have now sent me marketing material claiming their product preserves lean mass during GLP-1 treatment, two of them citing your publication as a source for the underlying composition figures. You may want to know that.

I have read your protein tables twice and I still cannot work out what I should eat. I appreciate that this is the honest position but it is not a useful one for a person in a supermarket.

My mother is eighty-one and on a low dose for her diabetes. Her weight is down nine kilograms and she now struggles to get out of a low chair, which she did not eighteen months ago. Nobody has measured anything. I do not know whether this is the drug, the weight loss, or being eighty-one, and neither does anybody I have asked.

The soft-tissue artefact point in your bone section is underplayed. In a patient losing twenty per cent of body mass the change in overlying tissue is well outside the range the calibration was validated over, and the published analyses do not report a sensitivity analysis for it. That is not a caveat, it is a gap.

Your piece treats the one-quarter rule as discredited and then quotes fractions of one third and two fifths from the substudies as though those were more solid. They are group means from a hundred and forty people. Physician, heal thyself.

I run analytical services and I object to the framing of your blind comparison. You bought our cheapest tier, published the number it produced alongside a competitor’s most thorough package, and called the result a spread. It is not a spread. It is three different products, priced accordingly, and your own table says so two columns to the right of the headline figure.

I submitted a vial to one of these services last year, got a result three points below what the vendor advertised, and did not know what to do with it. Your article explains why: I had one measurement on one vial, no method comparison, and no way to know if my vial was representative. I still do not know what to do with it, but I understand the shape of not knowing.

You disclose that two of these services advertise with you and then spend four thousand words on structural criticism of the sector they operate in. I cannot decide whether that is admirable independence or an elaborate way of appearing independent. Probably the former. I wanted to say that I noticed the question.

Your suggestion that laboratories publish the fact of a submission while keeping the result confidential is the first proposal I have read in this area that a laboratory could actually implement without breaching a client obligation. I have raised it internally.

Your selection-effect model assumes a supplier publishes results above a fixed threshold. Real behaviour is surely more complicated: a supplier might publish a poor result on a batch it has withdrawn, or publish everything for a period to establish credibility and then stop. The arithmetic is fine and the behavioural assumption is a cartoon.

You spend a page on the four-line calculation and then publish a reconstitution table anyway. Are you not providing exactly the pre-computed number you warned against?

A quibble on your dead-space figure. You give two to seven microlitres for insulin-type needles, which is right for fixed-needle syringes, but the detachable pen needle plus syringe hub combinations sold in this market are considerably worse and you should say so.

I have a certificate with an expiry date twenty-four months from manufacture and no stability data behind it, which your article says is a claim the documentation cannot support. The supplier tells me it is industry standard. Is it?

On the accreditation-scope point: most private buyers will not know which accreditation body to search. It would be more useful to publish the four or five registers that cover the laboratories this market actually uses than to tell readers the registers exist.

The composite test table you print as a model is unrealistic. No research supplier is going to run headspace GC and ion chromatography on every lot at these price points, and publishing an aspirational document as a benchmark just makes real certificates look worse than they are.

I found the section on the area postrema genuinely clarifying. I had assumed nausea was a stomach problem and had been treating it as one, unsuccessfully, for four months.

You describe biased agonism as "legitimate and probably important" and then decline to say which molecules are biased in which direction. That is a strange place to stop.

A small thing: you write "class B GPCR" and then "secretin-like receptor" as though these were different classifications. They are the same family under two naming conventions, and the piece would be clearer if it said so.

I have been on treatment for fourteen months and stopped losing weight at month eleven. Your piece says this is energy balance rather than receptor desensitisation. I would find that easier to accept if anybody had explained it to me at the start rather than after I had spent two months assuming the drug had stopped working.

I have read three separate articles this month describing cagrilintide as a GLP-1 agonist and one describing tirzepatide as "semaglutide with an extra bit". Thank you for the glossary. Please run it again.

Your ten-minute check told me in about ninety seconds that the batch number on my certificate appears nowhere on the vial. I wrote to the supplier and had a straightforward answer within a day: the certificate covers the bulk lot and the vial carries a fill code. I would never have known to ask.

You describe reused chromatogram images as a tell. I work in a contract laboratory and I would note that some data systems export a representative overlay rather than the individual injection, so identical-looking traces can occur legitimately across a batch series. It is still worth asking about; it is not the smoking gun your article implies.

On the accreditation-scope point: most private buyers will not know which accreditation body to search. It would be more useful to publish the four or five registers that cover the laboratories this market actually uses than to tell readers the registers exist.

I have a certificate with an expiry date twenty-four months from manufacture and no stability data behind it, which your article says is a claim the documentation cannot support. The supplier tells me it is industry standard. Is it?